Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Women with BRCA gene mutation develop breast cancer earlier than their ancestors

Women with a deleterious gene mutation are diagnosed with breast cancer almost eight years earlier than relatives of the previous generation who also had the disease and/or ovarian cancer, according to new research from The University of Texas MD Anderson Cancer Center.

12 Sep 2011

Nektar announces positive results from NKTR-102 Phase 2 study on metastatic breast cancer

Nektar Therapeutics announced today that positive results from the company's Phase 2 clinical study of NKTR-102 in patients with metastatic breast cancer were presented at the ASCO 2011 Breast Cancer Symposium in San Francisco, California.

12 Sep 2011

IBCRF awards TGen $50,000 to discover genetic origins of inflammatory breast cancer

The Inflammatory Breast Cancer Research Foundation (IBCRF) has awarded $50,000 to the Translational Genomics Research Institute (TGen) to discover the genetic origins of this rare and most deadly form of breast cancer.

7 Sep 2011

Combination of blood tests and ROMA algorithm receives FDA clearance to treat ovarian cancer

Approval last week by U.S. Food and Drug Administration (FDA) clears the path for nationwide use of tools that show the greatest specificity in estimating the risk of ovarian cancer in women with a pelvic mass.

7 Sep 2011

Breast cancer patients with BRCA1 mutation experience pCR after neoadjuvent chemotherapy

Nearly half of breast cancer patients carrying the BRCA1 gene mutation experience a complete pathological response (pCR) - the disappearance of all evidence of disease from the breast tissue and lymph nodes - regardless of disease stage after standard neoadjuvent chemotherapy, according to new research from The University of Texas MD Anderson Cancer Center.

7 Sep 2011

Fujirebio Diagnostics receives FDA 510(k) clearance for Risk of Ovarian Malignancy Algorithm test

Fujirebio Diagnostics, the industry leader in oncology biomarker assays, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market the company's HE4 Test in an algorithm called ROMA (HE4 EIA + ARCHITECT CA 125 II) to aid in assessing whether a premenopausal or postmenopausal woman who presents with an ovarian adnexal mass is at high or low likelihood of finding malignancy on surgery.

7 Sep 2011

Researchers discover mechanisms behind BRCA1 gene mutations in breast and ovarian cancer

It is widely known that mutations in the breast cancer susceptibility 1 (BRCA1) gene significantly increase the chance of developing breast and ovarian cancers, but the mechanisms at play are not fully understood. Now, researchers at Virginia Commonwealth University Massey Cancer Center have shown that certain BRCA1 mutations result in excessive, uncontrolled DNA repair, which challenges the prior assumption that mutations in BRCA1 only contribute to breast cancer through a reduction in function.

3 Sep 2011

Microtubule stability linked to increased sensitivity to paclitaxel

SCIENTISTS have discovered how blocking key cell signalling proteins could help boost the success rate of the tumour-shrinking drug paclitaxel, according to a study published in the journal Cancer Research today.

2 Sep 2011

New genetic screening program for families at high risk of colorectal cancer

UT Southwestern Medical Center has developed a new lifesaving genetic screening program for families at high risk of contracting colorectal cancer, a deadly yet highly preventable form of cancer.

2 Sep 2011

Boehringer Ingelheim initiates two afatinib phase II studies in HER2-positive breast cancer

Boehringer Ingelheim today announced the initiation of two phase II studies, 1200.89 and LUX-Breast 2, evaluating afatinib in patients with metastatic breast cancer, who have an overexpression of the erbB2 (HER2) protein, so called HER2-positive patients. Afatinib is an irreversible ErbB Family Blocker, which binds to all erbB-family kinases including erbB2.

29 Aug 2011

Individuals with BAP1 gene mutation more likely to develop mesothelioma

Scientists have found that individuals who carry a mutation in a gene called BAP1 are susceptible to developing two forms of cancer - mesothelioma, and melanoma of the eye.

29 Aug 2011

Tropical plants may contain basis of new and effective treatments for ovarian cancer

Tropical plants may contain the basis of new and effective treatments for ovarian cancer, according to researchers at the Universities of Strathclyde and Portsmouth.

25 Aug 2011

MicroRNA biomarkers provide guidance to develop specific gene therapies for glioblastoma

Patients suffering from an aggressive brain cancer will benefit from the results of a University of Illinois study that could advance the development of targeted gene therapies and improve prognosis.

23 Aug 2011

FDA approves Mayo Clinic's ovarian and breast cancer vaccines

Mayo Clinic has received investigational new drug approval from the Food and Drug Administration for two new cancer vaccines that mobilize the body's defense mechanisms to destroy malignant cells.

18 Aug 2011

Clinical trial to assess 6MP drug in women with advanced breast or ovarian cancer

A CANCER RESEARCH UK-funded trial of a new drug for patients with advanced breast or ovarian cancer due to inherited gene faults has been launched at the Oxford Experimental Cancer Medicine Centre (ECMC) at the University of Oxford.

17 Aug 2011

Researchers identify mesothelin antibody that could detect early-stage ovarian cancer

Using a new approach to developing biomarkers for the very early detection of ovarian cancer, researchers at Rush University Medical Center have identified a molecule in the bloodstream of infertile women that could one day be used to screen for those at high risk for the disease — or even those with early-stage ovarian cancer.

17 Aug 2011

Genetic culprit behind ovarian cancer discovered

A study has revealed that a single fault in a gene that normally helps the body to repair its DNA increases a woman's risk of ovarian cancer six-fold. One in every 11 women who carry the faulty gene is likely to develop ovarian cancer at some point in her life compared with a typical risk of about one in 70 for women in the general population, scientists said.

11 Aug 2011

Engineered T cells can eradicate deadly human ovarian cancer in immune-deficient mice

In a recent issue of Cancer Research, Daniel J. Powell, Jr., PhD, a research assistant professor of Pathology and Laboratory Medicine and Obstetrics and Gynecology at the Perelman School of Medicine at the University of Pennsylvania, showed for the first time that engineered human T cells can eradicate deadly human ovarian cancer in immune-deficient mice.

9 Aug 2011

Ovarian cancer gene discovered

A new study finds that around one woman in 70 is at risk of developing ovarian cancer, which claims more than 4,200 lives a year and this could be attributed to a faulty RAD15D gene. The gene raised the risk to one in 11.

8 Aug 2011

Women with RAD51D gene fault more likely to develop ovarian cancer

Cancer Research UK-funded scientists have discovered that women who carry a faulty copy of a gene called RAD51D have almost a one in 11 chance of developing ovarian cancer, the most significant ovarian cancer gene discovery for more than a decade, reveals a study in Nature Genetics1 today.

8 Aug 2011

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Women with BRCA gene mutation develop breast cancer earlier than their ancestors

Nektar announces positive results from NKTR-102 Phase 2 study on metastatic breast cancer

IBCRF awards TGen $50,000 to discover genetic origins of inflammatory breast cancer

Combination of blood tests and ROMA algorithm receives FDA clearance to treat ovarian cancer

Breast cancer patients with BRCA1 mutation experience pCR after neoadjuvent chemotherapy

Fujirebio Diagnostics receives FDA 510(k) clearance for Risk of Ovarian Malignancy Algorithm test

Researchers discover mechanisms behind BRCA1 gene mutations in breast and ovarian cancer

Microtubule stability linked to increased sensitivity to paclitaxel

New genetic screening program for families at high risk of colorectal cancer

Boehringer Ingelheim initiates two afatinib phase II studies in HER2-positive breast cancer

Individuals with BAP1 gene mutation more likely to develop mesothelioma

Tropical plants may contain basis of new and effective treatments for ovarian cancer

MicroRNA biomarkers provide guidance to develop specific gene therapies for glioblastoma

FDA approves Mayo Clinic's ovarian and breast cancer vaccines

Clinical trial to assess 6MP drug in women with advanced breast or ovarian cancer

Researchers identify mesothelin antibody that could detect early-stage ovarian cancer

Genetic culprit behind ovarian cancer discovered

Engineered T cells can eradicate deadly human ovarian cancer in immune-deficient mice

Ovarian cancer gene discovered

Women with RAD51D gene fault more likely to develop ovarian cancer

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Newsletters you may be interested in